Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ABBV

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 30 strange trades.

Benzinga

AbbVie Shares Fall On Mixed Bag Q1 Results, Cuts FY22 Profit Guidance

AbbVie Inc (NYSE:ABBV) reports Q1 adjusted EPS of $3.16, higher than the $2.89 reported a year ago and beating the consensus of $3.14. Overall sales increased 4.1% Y/Y (5.4% on an operational basis) to $13.54 billion, missing the consensus of $13.63 billion. The immunology portfolio generated $6.14 billion in sales, +6.9% (+8.1%…

Benzinga

AbbVie: Q1 Earnings Insights

AbbVie (NYSE:ABBV) reported its Q1 earnings results on Friday, April 29, 2022 at 07:44 AM. Here's what investors need to know about the announcement.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 6.18% on an annualized basis producing an average annual return of 18.59%. Currently, AbbVie has a market capitalization of $275.98 billion.

Benzinga

Preview: AbbVie's Earnings

AbbVie (NYSE:ABBV) is set to give its latest quarterly earnings report on Friday, 2022-04-29. Here's what investors need to know before the announcement. Analysts estimate that AbbVie will report an earnings per share (EPS) of $3.14.

Benzinga

Analyst Ratings for AbbVie

Analysts have provided the following ratings for AbbVie (NYSE:ABBV) within the last quarter:

Benzinga

AbbVie Walks Away From Parkinson's Drug Pact With BioArctic

AbbVie Inc (NYSE:ABBV) has ended a research partnership with Sweden's BioArctic, backing out further development of an experimental Parkinson's disease drug and other related medicines. A clinicaltrials.gov listing for ABBV-0805 says a Phase I study is "Withdrawn (Strategic considerations)." The partnership between AbbVie and BioArctic, which began in 2016, was focused on antibody drugs…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

AbbVie Whale Trades For April 19

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

If You Invested $1000 In AbbVie 5 Years Ago, Here's How Much You Would Have Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 7.23% on an annualized basis producing an average annual return of 20.59%. Currently, AbbVie has a market capitalization of $286.37 billion.

Benzinga

After Rallying More Than 10% Year-to-Date, There's More in Store for These 3 Mega-Cap Stocks

Amid concerns over the Fed’s aggressive interest rate posture, the Russia-Ukraine war, and the emergence of a new COVID-19 variant, which are exacerbating supply chain constraints, the stock market is expected to remain volatile in the coming months. Thus, well-established mega-cap companies are attracting investors’ attention, given their ability to…

StockNews.com

AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study

Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV)

Benzinga

This Investor Is Making Moves In Abbvie, Chipotle And Palo Alto Stock: Here's What He's Buying, What He's Selling

Virtus Investment Partners' Joe Terranova is shaking up his portfolio on Wednesday.

Benzinga

Check Out What Whales Are Doing With ABBV

Benzinga

5 Global Healthcare Stocks to Buy as BofA Warns of a "Recession Shock"

The healthcare industry is well-positioned to ride out a potential recessionary shock, thanks in-part to the inelastic demand for COVID-19 vaccines worldwide. Thus, we think investors could invest in fundamentally sound healthcare stocks Pfizer Inc. (PFE), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), Eli Lilly and Company (LLY), and Merck…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

This Is What Whales Are Betting On AbbVie

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 30 strange trades.

Benzinga

Analyst Ratings For AbbVie

AbbVie (NYSE:ABBV) has observed the following analyst ratings within the last quarter:

StockNews.com

5 Healthcare Stocks Likely to Withstand a Recession

The healthcare industry has attracted massive investor interest since the onset of the COVID-19 pandemic and could remain in the limelight as COVID cases surge again and necessitate the need for more COVID shots. In addition, the healthcare sector is known to withstand recessions relatively well. So, with several analysts…

Benzinga

AbbVie Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 39 strange trades.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

AbbVie Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

StockNews.com

3 Dividend Growth Stocks to Buy During This Market Correction

One characteristic of a high-quality stock is a consistent track record of hiking dividends. This indicates a strong business that can thrive in all types of economic conditions, and a management team focused on returning capital to shareholders. Here are 3 such ‘dividend growth’ stocks that investors should consider: Microsoft…

Benzinga

Looking At AbbVie's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 48 strange trades.

Benzinga

FDA Clears AbbVie's Rinvoq For Moderate To Severe Active Ulcerative Colitis

The FDA approved AbbVie Inc's (NYSE:ABBV) Rinvoq (upadacitinib) for adults patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blockers. This FDA approval is the first indication for Rinvoq in gastroenterology and is supported by efficacy and safety data from…

Benzinga

This Is What Whales Are Betting On AbbVie

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 16 strange trades.

Benzinga

AbbVie, Gedeon Richter Join Forces To Develop Dopamine Receptor Modulators For Neuropsychiatric Diseases

AbbVie Inc (NYSE: ABBV) and Gedeon Richter Plc have

Benzinga

AbbVie's Migraine Treatment Drug Touts Encouraging Data In Preventive Treatment Setting

AbbVie Inc (NYSE: ABBV) has reported data from the Phase 3 PROGRESS trial of atogepant (Qulipta) for the

1 … 8 9 10 11

People

Mangeet Kaur BounsMangeet

595 stories

Jaimini DesaiJaimini Desai

59 stories

Joe Terranova

23 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.